AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04332757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training intervention.
Description: The investigators have designed a phased 18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation. The rehabilitation element of the programme will specifically target pelvic floor function and core strength and stability (known collectively as Core Reconnection training) from weeks 6 to 24 postpartum, and the training element of the programme will contain resistance and high-intensity interval training (HIIT) from weeks 12 to 24 postpartum.
Study NCT01761396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Study NCT01761396 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UC
Study NCT03578523 — intervention group
Intervention type: OTHER
Intervention: 3 Tesla multiparametric MR
Description: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion). Each patient will have 3 renal MRI scans.
Study NCT03578523 — intervention group
Intervention type: OTHER
Intervention: renal histopathology scoring
Description: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication)
Study NCT03578523 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood and urine sampling
Description: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel,~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis
Study NCT03578523 — intervention group
Intervention type: BIOLOGICAL
Intervention: Iohexol clearance test
Description: Iohexol clearance to measure GFR within 1 week of the scan session
Study NCT02482233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENDD (NJOY)
Description: As described above.
Study NCT02482233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NRT (NicoDerm CQ)
Description: As described above.
Study NCT02482233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone counseling
Description: Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
Study NCT02482233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telephone counseling
Description: Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
Study NCT02482233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief advice
Description: Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible.
Study NCT02482233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: brief advice
Description: Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible.
Study NCT02482233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brochure
Description: A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.~Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure_%20For%20Posting.pdf
Study NCT02482233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: brochure
Description: A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.~Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure_%20For%20Posting.pdf
Study NCT06037135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: In the dexmedetomidine group, dexmedetomidine is administered at a rate of 0.5 μg/kg/h immediately after anesthesia induction and continued until the completion of the surgery. The research nurse, who did not participate in the study other than the management and preparation of the study medication, prepared 50mL of 0.9% normal saline for the control group and a mixture of dexmedetomidine 2 mL and 0.9% normal saline 48 mL (at a concentration of 4 μg/mL) for the dexmedetomidine group.
Study NCT06037135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% normal saline
Description: In the control group, a 0.9% normal saline infusion is initiated at the same rate immediately after anesthesia induction and continued until the end of the operation.
Study NCT01285258 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: hysterectomy
Description: excluding the uterus with saving ovaries
Study NCT02611232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victoza®
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
Study NCT02611232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
Study NCT01985061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BX2
Study NCT01985061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BX3
Study NCT01985061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BX4-Suspended
Description: Suspended
Study NCT01322958 — intervention group
Intervention type: DEVICE
Intervention: Pelvic Ultrasound
Description: Pelvic ultrasound performed by the emergency physician
Study NCT00595218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician behavior related to Patient Preference Survey
Description: Access to initial Patient preference survey results
Study NCT00595218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Preference Results
Description: Knowledge of Patient Preference Results
Study NCT01111903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase II: 20 mg/day in continuous regimen Phase I: 25 mg/day 21 days/28 with carboplatine AUC 5 + caelyx 30mg/m2
Study NCT01516788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phototesting
Description: Single MED dose on Day 2
Study NCT01326988 — intervention group
Intervention type: PROCEDURE
Intervention: Real-time ultrasound guided spinal anesthesia
Description: The neuraxial US scan will be performed with the patient in the sitting or lateral position with the hip and knees slightly flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance to administer the spinal anesthetic.
Study NCT03994146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Syringe containing 40 ml of Remifentanil 50 µg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery.
Study NCT03994146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Syringe containing 40 ml of Remifentanil 50 µg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery.
Study NCT03994146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Description: Syringe containing 40 ml of Sodium Chloride 9 mg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery.
Study NCT03994146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 9mg/mL
Description: Syringe containing 40 ml of Sodium Chloride 9 mg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery.
Study NCT04164563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Even-Up
Description: Orthotic shoe lift worn on contralateral foot to increase leg length
Study NCT01549730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18F-Fluoroazomycin Arabinoside (18F-FAZA)
Description: A PET scan is an imaging test that uses special radioactive dyes to measure different aspects of how your cancer acts. In this study, a dye called 18F-Fluoroazomycin Arabinoside (18F-FAZA) will be used to measure hypoxia levels in tumours. Health Canada has not approved FAZA for general use, but has approved it for use in this study.
Study NCT00324038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: buprenorphine transdermal system 5, 10 and 20 mg
Study NCT00324038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine paracetamol
Description: combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
Study NCT02401919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tell-us Card
Description: Patients will be invited on a daily basis, during their stay in the hospital, to state what is important for them at that moment or before discharge
Study NCT01109095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER.CAR CMV-specific CTLs
Description: HER2.CAR CMV-specific CTLs will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The patient will get one of the following doses:~* 1 x 10\^6/m\^2~* 3 x 10\^6/m\^2~* 1 x 10\^7/m\^2~* 3 x 10\^7/m\^2~* 1 x 10\^8/m\^2
Study NCT01514903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP0908
Description: SINGLE DOSE , CROSS OVER
Study NCT01514903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: viagra
Description: single dose, cross over
Study NCT01668212 — intervention group
Intervention type: PROCEDURE
Intervention: Doppler ultrasound
Description: Doppler Ultrasound
Study NCT05478187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional visual cues - Control group
Description: 10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the traditional cues (stripes on the floor)
Study NCT00663715 — intervention group
Intervention type: OTHER
Intervention: Observation of the Sciatic Nerve
Description: Ultrasound will be used to determine the location of the Sciatic Nerve using a lateral mid-thigh approach.
Study NCT03134430 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Injection of Normal saline around peripheral nerve
Study NCT03134430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peripheral Nerve block
Description: Injection of local anesthetics around peripheral nerve
Study NCT00217724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glutamine
Description: Given orally
Study NCT00217724 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT04487899 — intervention group
Intervention type: DEVICE
Intervention: Analysis of heart rate variability
Description: The HR HRV interval of the heartbeat (variations in the time interval between beats) was used as a measure of autonomous modulation, and the Firstbeat Bodyguard monitor (Firstbeat Technologies, Jyväskylä, Finland) was used to record HRV data during the session with emergency situations in the flight simulator. Data was downloaded from the devices to a computer using Firstbeat Uploader software (Firstbeat Technologies), and all R-R interval series were imported into the Kubios software package (University of Eastern Finland, Kuopio, Finland). To calculate the autonomous equilibrium, the commonly used HRV method based on the Poincaré graph was used (Brennan et al., 2001; Mourot et al., 2004).
Study NCT02539784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kit for Spinal Cord Stimulator System  SCS Systems  : PRECISION® System
Description: 3 frequencies of SCS are tested for each patient : 50, 100 and 130 Hz
Study NCT03968926 — intervention group
Intervention type: OTHER
Intervention: Arterial pressure management during circulatory support by VA-ECMO
Description: Norepinephrine continuous infusion to maintain mean arterial pressure above 65 mmHg or at a higher level depending of the perfusion pressure targeted for the patient (mean arterial pressure between 65 and 85 mmHg)
Study NCT02270216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: static hand grip exercise
Description: The static exercise pressor response will be tested using isometric handgrip of the left hand. The forearm will be supported on an arm rest with elbow flexed. The maximum voluntary contraction force will be measured as the best of three attempts. After 2 minute rest, subjects will perform 2 minute of isometric hand grip contraction at 30% MVC. Circulatory occlusion(50 mmHg supra-systolic pressure) will start at 1.30 min and continued for 2 minute after the end of the isometric handgrip exercise. Following release of the cuff there will be a further 2 minutes recovery. The blood pressure and heart rate will be measured at the end of each minute during rest, isometric handgrip, circulatory occlusion and recovery. Subjects will be instructed to breathe normally during the test and avoid any Valsalva maneuver; breathing frequency will be monitored during the handgrip pressor test using capnography.
Study NCT02270216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cycling exercise
Description: The dynamic exercise will be with the subject sitting on a cycle ergometer (Monark 828 E). Resting heart rate will be measured for 2 minutes before the start of exercise. The exercise level will be limited to 50% of the estimated maximum heart rate reserve. Maximum heart rate will be estimated as 207-0.7\*age and heart rate reserve (HRR) as maximum minus resting heart rate. Subjects will pedal at 50 rpm for 1 min with no load and then 3 minutes against a load of 0.5 Kp (25W) increasing to a load of 1 Kp for the next 3 minutes and to 1.5 Kp, if necessary, for a further 3 minutes until the target heart rate of 50% HRR is reached.~Subjects will be asked about their level of perception of dyspnea using a visual analog scale every 3 minutes at the end of each load. At the end of the exercise, the subjects will sit for ten minutes.
Study NCT02840955 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Staphefekt SA.100
Study NCT02840955 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04074031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound Therapy (Exablate® 4000 Type 1.1)
Description: The Exablate® 4000 Type 1.1 model designed for noninvasive ablation of brain tissue is an MRI-guided transcranial ultrasound system (MRgFUS). The goal of the Exablate Neuro system is to precisely guide the focus of the ultrasound energy on the target region. The focused ultrasound energy is then repeatedly transmitted to the target until the desired result is achieved. Targeting is performed using MRI acquired during treatment. The treatment process is constantly monitored by closed-loop thermal feedback in real time, under the supervision of the treating physician. Once targeting is complete, the treatment outcome is confirmed by MRI sequences immediately after treatment. The Exablate Neuro is compatible with Siemens 3 Tesla MRI.
Study NCT03419104 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: preoperative walk test
Description: Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
Study NCT01478828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: oral qd varying dose escalations/de-escalations
Study NCT01713088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy
Study NCT03585231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate access to novel messaging program intervention
Description: The experimental arm includes an immediate intervention using a novel messaging program for smoking cessation.
Study NCT03585231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immediate access to standard of care messaging program intervention
Description: The immediate control intervention uses a standard of care messaging program for smoking cessation.
Study NCT01713088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: YOT (usual services)
Study NCT01246713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen liquid formulation
Description: Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
Study NCT01246713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen solid formulation
Description: Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
Study NCT01620723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Breastfeeding Counselling
Description: An intervention will be developed during the first part of the study. The intervention is supposed to consist of evidence based actions to support the metabolic adaptation of the newborn, establishment of the milk production of the mother and increase the breastfeeding self efficacy of the mother.
Study NCT03585231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed access to novel novel messaging program intervention
Description: The delayed control intervention uses the novel messaging program for smoking cessation.
Study NCT00561457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bard Luminexx Iliac Stent and Delivery System
Description: Iliac Stenting
Study NCT04458207 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral prosthetic rehabilitation
Description: Individual treatment options will be discussed with the participants individually and rehabilitation will be provided as agreed by the dentist and the participant. The rehabilitation will include fixed prosthodontics. The procedures will involve a control phase involving scaling, root planing oral hygiene instructions etc., extractions and bone augmentation when needed and temporary removable dentures. Restoration of the lost vertical dimension (if needed) with occlusal splints, tooth preparations, placement of dental implants (if needed) and finally cementation of dental crowns. The rehabilitation phase is estimated to take approximately 3-18 months, or more.
Study NCT04458207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral prosthetic rehabilitation
Description: Individual treatment options will be discussed with the participants individually and rehabilitation will be provided as agreed by the dentist and the participant. The rehabilitation will include fixed prosthodontics. The procedures will involve a control phase involving scaling, root planing oral hygiene instructions etc., extractions and bone augmentation when needed and temporary removable dentures. Restoration of the lost vertical dimension (if needed) with occlusal splints, tooth preparations, placement of dental implants (if needed) and finally cementation of dental crowns. The rehabilitation phase is estimated to take approximately 3-18 months, or more.
Study NCT04139668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 380 MG [Vivitrol]
Description: Three 4ml intramuscular injections of naltrexone 380mg (Vivitrol) administered over 12 weeks (one injection every 4 weeks)
Study NCT04139668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy and Cognitive Behavioral Therapy
Description: Weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy (MET/CBT), based upon the Brief Counselling for Marijuana Dependence Manual published by the Substance Abuse and Mental Health Services Administration (SAMHSA), for 12 weeks
Study NCT03221283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy group
Description: The experimental group received 13 group music sessions over a three-month period. Different method of music therapy will be used to improve the emotion experience, emotion regulation, emotional control and emotional expression.